Skip to content

Dermal Substitution in Pediatric Burns

Dermal Substitution in Paediatric Burns: A Prospective Case Series

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05309720
Acronym
GlyPeB
Enrollment
20
Registered
2022-04-04
Start date
2022-09-01
Completion date
2025-11-01
Last updated
2024-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Burns, Burn Scar

Keywords

Burns, Scar quality, Pediatric

Brief summary

The standard treatment of deep dermal to full thickness burns is surgical removal of the burn followed by skin transplantation. Dermal substitutes are increasingly used in the treatment of deep burns to replace lost dermis. Preservation of the collagen and elastin in the acellular human dermal substitute Glyaderm provides a more elastic scar. It is unknown what the effect of Glyaderm on scar quality is in a solely paediatric population. The objective of this case series is to investigate scar maturation and scar quality when applying Glyaderm in deep dermal to full thickness burns in a pediatric population aged ≤15 years old.

Interventions

PROCEDUREGlyaderm

All included patients will undergo full thickness removal of the burned skin or adequate debridement of all necrotic tissue. Next, the dermal substitute Glyaderm followed by a split thickness skin graft will be transplanted on the wound.

Sponsors

Radboud University Medical Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

prospective case series

Eligibility

Sex/Gender
ALL
Age
No minimum to 15 Years
Healthy volunteers
No

Inclusion criteria

1. Age ≤15 years old 2. Burn wounds requiring skin grafting 3. Written informed consent provided by 1. The participant's parent(s)/guardian (\<12 years of age) 2. The participant's parent(s)/guardian and the participant itself (12-15 years old)

Exclusion criteria

1. Burn wound of ≤30 cm2 2. Infected burn wounds: clinical symptoms in combination with positive wound swabs 3. Patients/parents with insufficient knowledge of the Dutch or English language, since they would not be able to complete the POSAS questionnaire.

Design outcomes

Primary

MeasureTime frameDescription
Scar quality (clinician)12 monthsScar quality measured using the Patient and Observer Scar Assessment Scale (POSAS) Observer Scale, which rates the scar from 1 (=like normal skin) to 10 (=worst scar imaginable).

Secondary

MeasureTime frameDescription
Wound epithelialization5-7 days after STSG applicationWound epithelialization is the percentage of the graft with a vital skin graft and healed graft interstices.
Wound healing timedetermined in the first several days to weeks after STSG application\>95% epithelialization of the wound area is considered as healed
Donor site healing timedetermined in the first several days to weeks after STSG application\>95% epithelialisation of the donor site wound surface area is considered as healed
Scar surface areaday of surgery (day 0) and 3, 6 and 12 months post-surgeryThe scar surface area is calculated using the surgery wound as reference area
Clinical assessment of the graft take5-7 days after STSG applicationTake of the split thickness skin graft (STSG) in percentages. The take is defined as STSG that appears vital and is adherent to the wound bed.
Occurrence of scar contracturesUp to 12 months post-surgeryScar contractures often occur in children with deep dermal and full thickness burn wounds.
Occurrence of scar hypertrophyUp to 12 months post-surgeryScar hypertrophy often occurs in children with deep dermal and full thickness burn wounds.
Range of motion of affected joints3, 6 and 12 months post-surgeryWhen joints are affected due to the burn wound, the range of motion of the affected joint(s) will be monitored during follow-up.
Scar quality (participant)3, 6 and 12 months post-surgeryScar quality measured using the Patient and Observer Scar Assessment Scale (POSAS) Patient Scale, rating the scar from 1 (=like normal skin) to 10 (=worst scar imaginable).

Countries

Netherlands

Contacts

Primary ContactMilly van de Warenburg, MD
milly.vandewarenburg@radboudumc.nl0031 24 361 1111

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026